[1] |
Talukdar FR, di Pietro M, Secrier M, et al. Molecular landscape of esophageal cancer: implications for early detection and personalized therapy[J]. Ann N Y Acad Sci, 2018, 1434(1): 342-359. DOI: 10.1111/nyas.13876.
|
[2] |
Musa IH, Musa TH, Musa HH, et al. Esophageal cancer epidemiology, diagnosis, and management in Sudan—a review[J]. Med J Malaysia, 2021, 76(5): 691-697.
pmid: 34508376
|
[3] |
Li C, Wang X, Wang L, et al. Clinical practice and outcome of radiotherapy for advanced esophageal squamous cell carcinoma between 2002 and 2018 in China: the multi-center 3JECROG survey[J]. Acta Oncol, 2021, 60(5): 627-634. DOI: 10.1080/0284186X.2021.1902564.
|
[4] |
Gao RX, Wang Z, Liu Q, et al. MicroRNA-105 plays an independent prognostic role in esophageal cancer and acts as an oncogene[J]. Cancer Biomark, 2020, 27(2): 173-180. DOI: 10.3233/CBM-180.
pmid: 31796663
|
[5] |
Liu ZQ, Wu SS, Wang L, et al. Prognostic value of microRNA-497 in various cancers: a systematic review and meta-analysis[J]. Dis Markers, 2019, 2019: 2491291. DOI: 10.1155/2019/2491291.
|
[6] |
Zou GC, Wang R, Wang MH. Clinical response and prognostic significance of serum miR-497 expression in colorectal cancer[J]. Cancer Biomark, 2019, 25(1): 11-18. DOI: 10.3233/CBM-181902.
pmid: 31006664
|
[7] |
徐燕, 黄建航, 郑志平, 等. miR-383调控血管生成因子VEGFA的表达并抑制血管生成[J]. 福建医科大学学报, 2019, 53(2): 71-75.
|
[8] |
赫捷, 中国抗癌协会食管癌专业委员会. 食管癌规范化诊治指南[M]. 2版. 北京: 中国协和医科大学出版社, 2013.
|
[9] |
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
|
[10] |
Wang QF, Peng L, Li T, et al. Postoperative chemotherapy for thoracic pathological T3N0M0 esophageal squamous cell carcinoma[J]. Ann Surg Oncol, 2020, 27(5): 1488-1495. DOI: 10.1245/s10434-019-08112-1.
|
[11] |
Chen S, Yin WW, Bi K, et al. MicroRNA-497 attenuates cerebral infarction in patients via the TLR4 and CREB signaling pathways[J]. Int J Mol Med, 2018, 42(1): 547-556. DOI: 10.3892/ijmm.2018.3611.
pmid: 29620142
|
[12] |
Gao C, Li Y, Liu L. MicroRNA-497 regulates the proliferation of clear cell renal cell carcinoma via interleukin-6 receptor[J]. Biotechnol Biotechnol Equip, 2019, 33(1): 1108-1115. DOI: 10.1080/13102818.2019.1640074.
|
[13] |
Zhang LH, Yao LW, Zhou W, et al. MiR-497 defect contributes to gastric cancer tumorigenesis and progression via regulating CDC42/ITGB1/FAK/PXN/AKT signaling[J]. Mol Ther Nucleic Acids, 2021, 25: 567-577. DOI: 10.1016/j.omtn.2021.07.025.
|
[14] |
赵亮, 张帅, 王海龙. 结肠癌组织中miR-383、Notch1 mRNA表达变化与患者临床病理参数及预后的关系[J]. 山东医药, 2021, 61(29): 19-22. DOI: 10.3969/j.issn.1002-266X.2021.29.005.
|
[15] |
Zhu CY, Huang Q, Zhu HY. MiR-383 inhibited the cell cycle progression of gastric cancer cells via targeting cyclin E2[J]. DNA Cell Biol, 2019, 38(8): 849-856. DOI: 10.1089/dna.2019.4624.
pmid: 31170011
|
[16] |
李振淼, 李文. miR-383通过下调细胞周期相关蛋白的表达抑制小鼠卵泡颗粒细胞的增殖[J]. 细胞与分子免疫学杂志, 2019, 35(6): 518-525. DOI: 10.13423/j.cnki.cjcmi.008824.
|
[17] |
Yang G, Xiong GB, Cao Z, et al. MiR-497 expression, function and clinical application in cancer[J]. Oncotarget, 2016, 7(34): 55900-55911. DOI: 10.18632/oncotarget.10152.
pmid: 27344185
|
[18] |
Fridrichova I, Kalinkova L, Karhanek M, et al. MiR-497-5p decreased expression associated with high-risk endometrial cancer[J]. Int J Mol Sci, 2020, 22(1): 127. DOI: 10.3390/ijms22010127.
|
[19] |
Sun XL, Wang X, Dong G, et al. Expression level of miR-383-5p in colorectal cancer patients following neoadjuvant chemotherapy and its clinical significance in the prognosis[J]. Minerva Med, 2023, 114(4): 485-490. DOI: 10.23736/S0026-4806.20.06656-2.
|